Home » Stocks » IMAB

I-Mab (IMAB)

Stock Price: $54.67 USD 2.83 (5.46%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 3.85B
Revenue (ttm) 4.29M
Net Income (ttm) -212.14M
Shares Out 70.50M
EPS (ttm) -287.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $54.67
Previous Close $51.84
Change ($) 2.83
Change (%) 5.46%
Day's Open 52.75
Day's Range 51.00 - 54.86
Day's Volume 169,815
52-Week Range 10.63 - 57.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 4 weeks ago

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 1 month ago

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...

PRNewsWire - 1 month ago

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...

PRNewsWire - 1 month ago

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...

GuruFocus - 2 months ago

In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, a...

Other stocks mentioned: IVBXF
Seeking Alpha - 2 months ago

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic De...

Other stocks mentioned: BGNE, BNTX, CALT, MRK, PFE, TMO
PRNewsWire - 2 months ago

SHANGHAI and GAITHERSBURG, Md., Nov. 13, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 2 months ago

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 2 months ago

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...

PRNewsWire - 2 months ago

SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development a...

PRNewsWire - 2 months ago

SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 4 months ago

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab (Nasdaq: IMAB) today jointly a...

Zacks Investment Research - 4 months ago

I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Investment Research - 4 months ago

Companies in the news are: IMAB, LMPX, DPW, ANPC

Other stocks mentioned: ANPC, DPW
Seeking Alpha - 4 months ago

Shanghai's I-Mab out-licensed ex-China rights for lemzoparlimab, its anti-CD47 mAb, to AbbVie in a blockbuster $2 billion agreement.

Other stocks mentioned: ABBV
InvestorPlace - 4 months ago

I-Mab (IMAB) is seeing gains to IMAB stock on Friday after the biopharma company announced news of a deal with AbbVie (ABBV).

The Motley Fool - 4 months ago

The deal could be the largest-ever out-licensing agreement by a Chinese biotech.

Other stocks mentioned: ABBV
Market Watch - 4 months ago

Shares of I-Mab IMAB, +0.47% soared 17% in premarket trading Friday toward a record high, after the China-based biotechnology company announced a collaboration agreement with AbbVie Inc.

PRNewsWire - 4 months ago

SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 4 months ago

NORTH CHICAGO, Ill., and SHANGHAI, Sept.

GuruFocus - 4 months ago

Shares of Chinese biopharmaceutical company I-Mab (NASDAQ:IMAB) continued to impress following the recent half-year results for the period ended June 30.

Seeking Alpha - 4 months ago

I-Mab's (IMAB) CEO Joan Huaqiong Shen on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 4 months ago

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort agains...

PRNewsWire - 5 months ago

SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 5 months ago

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commer...

PRNewsWire - 5 months ago

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 6 months ago

SHANGHAI and GAITHERSBURG, Md., July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

PRNewsWire - 7 months ago

SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and comme...

About IMAB

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin (TJ101), a long-acting human growth hormone that has completed Phase II clinical trials to treat pediatric growth hormone deficiency; and Olamkicept... [Read more...]

Industry
Biotechnology
IPO Date
Jan 17, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMAB
Full Company Profile

Financial Performance

In 2019, I-Mab's revenue was 30.00 million, a decrease of -44.22% compared to the previous year's 53.78 million. Losses were -1.45 billion, 260.4% more than in 2018.

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for I-Mab stock is "Strong Buy." The 12-month stock price forecast is 54.42, which is a decrease of -0.46% from the latest price.

Price Target
$54.42
(-0.46% downside)
Analyst Consensus: Strong Buy